The Stanford Amyloid Center is an active participant in and leader of many clinical trials. Listed below are current/active clinical trials at our Center.
Please speak to your Stanford Amyloid Center team to see if any clinical trial opportunities are available for you.
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients with Symptomatic Transthyretin Amyloid Cardiomyopathy (NCT03458130)
An Open-Label Extension and Safety Monitoring Study of Patients With Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201” (NCT03536767)
A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis (NCT03336580)
PET/MRI Evaluation of Cardiac Amyloid (NCT03119558)
A Phase 3 Multicenter, Randomized, Double-blind, Extension Study to Evaluate The Safety Of Daily Oral Dosing Of Tafamidis Meglumine (PF-06291826) 20 Mg Or 80 Mg In Subjects Diagnosed With Transthyretin Cardiomyopathy (TTR-CM) (NCT02791230)
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis (NCT03201965)
Expanded Access Protocol of Patisiran for Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With Polyneuropathy (NCT02939820)
Expanded Access Program for Inotersen (ISIS 420915) in Patients With Hereditary Transthyretin Amyloidosis (hATTR) (NCT03400098)